EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers

Yehya Tlaiss iD, Ali Harajli, Ehab Al Mashtoub, Atef Salame Nasreddine iD, Tony Badawi, Alaa Tarchichi iD, Mohamad Tlais iD

Journal of Ophthalmology · 2026-01 · 2026 (1)

DOI: 10.1155/joph/8124348 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Ophthalmology, online erschienen am 13.07.2026. Verfasst von Yehya Tlaiss und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Balamand, Beirut, Lebanon, balamand.edu.lb. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) because of its immunomodulatory and anti‐inflammatory benefits. However, long‐term exposure can cause HCQ‐induced retinopathy, a potentially irreversible adverse effect in which early detection is critical. This review summarizes the literature on the reported prevalence of HCQ‐related retinal toxicity in SLE, highlights consistently supported risk modifiers (including higher daily dose relative to real body weight, longer duration/cumulative exposure, and renal impairment), and synthesizes current screening strategies centered on multimodal structural and functional testing. Spectral‐domain optical coherence tomography (SD‐OCT), fundus autofluorescence (FAF), standard automated perimetry, and multifocal electroretinography (mfERG) are frequently emphasized as complementary tools for earlier detection, while emerging approaches such as OCT angiography‐derived metrics and pharmacokinetic measures remain exploratory. Real‐world screening adherence is often suboptimal, underscoring the need for implementation strategies that align dosing, risk stratification, and ophthalmic monitoring. Future work should standardize diagnostic definitions, clarify optimal screening intervals across risk strata, and prospectively validate promising biomarkers and automated screening workflows.

Schlagwörter

Stichwörter der Autor:innen

hydroxychloroquineoptical coherence tomographyretinal toxicityscreening strategiessystemic lupus erythematosus

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Balamand, Beirut, Lebanon, balamand.edu.lb.
  • Faculty of Medicine, Lebanese American University, Beirut, Lebanon, lau.edu.lb.
  • Faculty of Medicine, University of Balamand, Beirut, Lebanon, balamand.edu.lb.
  • Faculty of Medicine, Beirut Arab University, Beirut, Lebanon, bau.edu.lb.

ORCID-Profile: Yehya Tlaiss, Atef Salame Nasreddine, Alaa Tarchichi, Mohamad Tlais

Zitieren

APA

Tlaiss, Y., Harajli, A., Mashtoub, E. A., Nasreddine, A. S., Badawi, T., Tarchichi, A., & Tlais, M. (2026). Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers. Journal of Ophthalmology, 2026(1). https://doi.org/10.1155/joph/8124348

Vancouver

Tlaiss Y, Harajli A, Mashtoub EA, Nasreddine AS, Badawi T, Tarchichi A, et al. Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers. Journal of Ophthalmology. 2026;2026(1). doi:10.1155/joph/8124348

BibTeX
@article{Tlaiss2026,
  author = {Tlaiss, Yehya and Harajli, Ali and Mashtoub, Ehab Al and Nasreddine, Atef Salame and Badawi, Tony and Tarchichi, Alaa and Tlais, Mohamad},
  title = {Hydroxychloroquine Retinopathy in Systemic Lupus Erythematosus: Risk Factors, Screening, and Emerging Biomarkers},
  journal = {Journal of Ophthalmology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/joph/8124348}
}
Kostenlos starten →